--- title: "Dr. Yajing Zhang: Lymphoma Has Many Subtypes—Why Is Genetic Testing So Important?" url: "https://www.yyhmedical.com/en/news/lymphoma-genetic-testing-zhang-yajing" type: Article inLanguage: en-US category: Expert Insights datePublished: 2026-05-15 --- # Dr. Yajing Zhang: Lymphoma Has Many Subtypes—Why Is Genetic Testing So Important? > Dr. Yajing Zhang explains how genetic testing can support more precise lymphoma diagnosis, help assess prognosis, guide targeted treatment choices, and enable dynamic disease monitoring—making truly individualized care possible. Summary: Dr. Yajing Zhang explains why genetic testing has become an important part of modern lymphoma care. Because lymphoma includes many distinct subtypes, genetic testing can help refine the diagnosis, identify high-risk alterations such as “double-hit” rearrangements, guide the selection of targeted therapies such as BTK inhibitors, and provide additional information when considering advanced treatments including CAR-T therapy. Liquid biopsy and circulating tumor DNA (ctDNA) can also be used in some settings for dynamic monitoring during and after treatment. Together, these tools help move lymphoma care away from a one-size-fits-all approach toward treatment strategies tailored to each patient. *Hello, I'm Dr. Yajing Zhang.* *In clinic, I often see the same situation: patients and families have only just begun to process a lymphoma diagnosis when their doctor recommends another test that may sound complicated—genetic testing.* *Many people understandably ask, “Doctor, hasn't the pathology report already confirmed the diagnosis? Why do I still need genetic testing? It's another significant expense—is it really necessary?”* *These are very reasonable concerns. Today, I'd like to explain why genetic testing can be such an important step in lymphoma care. One way to think about it is as a personalized “road map” that helps us tailor treatment more closely to the biology of your disease.* **1\. Lymphoma Is Not One Disease—It Is a Large Family of Diseases** First, it's important to understand that “lymphoma” is not a single disease. It is an umbrella term covering more than 100 subtypes. Think of the word “fruit”: apples, bananas, and grapes are all fruit, but they are very different from one another. The same is true for lymphoma. Indolent lymphomas, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and many other subtypes can behave very differently. Traditional pathology helps identify what type of lymphoma is present, but in some cases it may not tell us the whole biological story. Even within the same lymphoma subtype, tumors can differ at the molecular level. Genetic testing looks more deeply at the tumor's “genetic code” to identify abnormalities that may influence how quickly it grows, how aggressive it is, and—most importantly—what treatments it may be more likely to respond to. This is why lymphoma treatment should not follow a one-size-fits-all model. The goal is to build an individualized treatment plan around the specific features of each patient's disease. **2\. Genetic Testing: A Personalized Road Map for Diagnosis and Treatment** This “road map” can help answer three key questions: **(1) Can We Make the Diagnosis More Precise?** Lymphoma can sometimes be difficult to classify correctly at the initial diagnosis, especially when it arises in less common sites such as the eye, nose, or central nervous system. By analyzing the genetic features of tumor cells, genetic testing can provide additional information that helps doctors define the lymphoma subtype more precisely. The more accurate the starting point, the more confidently the treatment plan can be mapped out. **(2) What Can Genetic Findings Tell Us About Prognosis?** Even among patients with the same diagnosis—for example, diffuse large B-cell lymphoma—some respond well to standard treatment and remain disease-free for years, while others are more likely to relapse. Part of that difference can be explained by the tumor's genetic features. For example, the presence of MYC and BCL2 rearrangements—often referred to as a “double-hit” pattern—may indicate more aggressive disease and a less favorable prognosis. Knowing this early can help the care team assess risk more clearly and consider whether a more individualized treatment strategy is appropriate, rather than waiting until the disease relapses. **(3) Can Genetic Testing Help Guide Treatment Choices?** This is one of the most practical reasons for doing genetic testing: it may reveal molecular targets that can help guide treatment. Targeted therapy: For example, finding an MYD88 mutation may, in certain lymphoma settings, suggest potential sensitivity to a BTK inhibitor such as zanubrutinib. In other words, identifying a molecular “weak point” in the tumor may help doctors choose treatment more purposefully and reduce unnecessary trial-and-error. Advanced therapies such as CAR-T: For patients with relapsed or refractory lymphoma, CAR-T cell therapy may offer another treatment option. Genetic testing can provide additional information about tumor biology that may help doctors assess the overall treatment strategy, anticipate response patterns and potential risks, and consider whether combination approaches may be appropriate. **3\. Dynamic Monitoring: A Real-Time View of the Treatment Journey** Treatment decisions do not stop once therapy begins. During treatment and follow-up, a “liquid biopsy” using peripheral blood may be used to monitor changes in circulating tumor DNA (ctDNA). You can think of this as the “live traffic” function on a navigation app. In some settings, ctDNA can reveal molecular signs of recurrence before they become visible on conventional imaging such as CT, giving the medical team an opportunity to investigate further and adjust the treatment plan when appropriate. Facing complex tests and an unfamiliar diagnosis can be overwhelming. But advances in modern medicine mean that many lymphoma subtypes can now be cured or controlled for long periods, and treatment options continue to expand. Genetic testing is one of the tools that can help bring greater clarity to that process. Its purpose is not simply to add another test, but to give patients and doctors more information for choosing a more individualized path forward. It helps move care from a broad, one-size-fits-all approach toward a treatment strategy designed around the individual patient. That is the goal of truly personalized medicine. --- Original (HTML):https://www.yyhmedical.com/en/news/lymphoma-genetic-testing-zhang-yajing This is a clean Markdown mirror for large language models; the original page is authoritative.